Griese, M., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., . . . Daines, C. L. (2021). Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med.
Stile di citazione ChicagoGriese, Matthias, et al. "Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People With Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial." Am J Respir Crit Care Med 2021.
Citazione MLAGriese, Matthias, et al. "Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People With Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial." Am J Respir Crit Care Med 2021.